A Market Observation: 
In a recent Market Insight, we discussed how life sciences data platforms are moving from adjacent intelligence to embedded infrastructure. The underlying reason is simpler: durable value in healthcare increasingly sits inside operational workflows. As one executive working across pharmacy, retail data, and clinical trial infrastructure recently observed:

“Workflow is the new moat.”

The statement reflects a structural shift in how competitive advantage is built in healthcare and life sciences technology markets.

For much of the past decade, value was often associated with tools, datasets, or analytics platforms that provided insight into complex biological or clinical information.

Companies that could aggregate or analyze data were viewed as holding durable advantages.

Today, the market increasingly rewards something different: control over where the work actually happens.

Why Workflow Matters
In healthcare and life sciences, the most durable businesses tend to sit directly inside operational workflows.

These workflows emphasize execution environments, for example:

• laboratory testing and sample processing
• clinical trial sites and patient recruitment networks
• diagnostic testing platforms
• pharmacy dispensing and medication management
• clinical and research operations infrastructure

This is why many of the most valuable companies in healthcare technology historically have been tied to operational environments: laboratory systems, diagnostic platforms, clinical networks, and instruments used in everyday research and care delivery.

In each case, the technology does more than analyze information. It runs the workflow.

Data Without Workflow Is Becoming Harder to Defend
This distinction is becoming even more important as artificial intelligence improves the ability to search, summarize, and synthesize large datasets.

Platforms built primarily around data aggregation or analytics are increasingly vulnerable to commoditization as AI lowers the barriers to extracting insights from large volumes of information.

By contrast, systems embedded directly in operational workflows benefit from a powerful reinforcing cycle:

• the workflow generates proprietary data
• the data improves the software and models
• the improved system strengthens the workflow

This feedback loop creates the type of mechanical leverage that strategic buyers often seek in acquisitions.

In effect, the workflow becomes the source of both data advantage and customer retention.

Strategic Implications for Buyers
For corporate development teams evaluating technology assets in healthcare, a useful question is emerging:

Does the asset control the workflow, or does it sit adjacent to it?

Assets that control workflow often create durable strategic advantages. They influence how work is performed and become deeply embedded in operational processes.

Assets that remain adjacent to the workflow—providing analysis, intelligence, or external tools—may still be valuable but often require a different strategy to achieve long-term defensibility.

This distinction helps explain several recurring patterns in healthcare M&A.

Strategic buyers frequently prioritize companies that expand their operational footprint—laboratories, clinical networks, diagnostics platforms, and development infrastructure—because these businesses generate both data and recurring activity.

Financial sponsors also often gravitate toward healthcare platforms tied to operational execution – labs, clinical services, diagnostics, and pharmacy infrastructure.

AI Is Reinforcing the Importance of Workflow
Artificial intelligence is likely to strengthen this trend rather than weaken it.

Advanced models require large volumes of high-quality, domain-specific data. The most reliable way to generate that data is through systems that operate directly within real-world workflows.

Laboratories generate experimental data.

Clinical systems generate patient data.

Pharmacies generate medication data.

These environments are where real-world data is created.

Platforms that control these environments are positioned to build increasingly valuable data assets over time.

As a result, the companies best positioned to benefit from AI in healthcare may not simply be those building the most sophisticated models. They may be those controlling the operational systems where the data originates.

The Emerging Structure of Healthcare Technology
The healthcare technology stack is gradually reorganizing around this idea.

Information platforms provide insight.

AI models provide analytical capability.

But workflow systems determine where value accumulates.

Companies that control execution—whether through laboratories, clinical infrastructure, diagnostic platforms, or operational software—are increasingly able to capture both the data and the decision layer.

In that context, a casual comment reveals a deeper strategic framework:

Workflow is the new moat.